专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明专利

CA2362315A1 IMPLANTABLE DEVICE FOR ACCESS TO A TREATMENT SITE 未知
公开(公告)号：CA2362315A1
公开(公告)日：2000-09-14
申请号：CA2362315
申请日：2000-02-29
申请人： DURECT CORP
发明人： GILLIS EDWARD M , THEEUWES FELIX
IPC分类号： A61M39/02 , A61M31/00 , A61M25/06
摘要： The present invention provides an implantable guide (10) for access to a treatment site. The implantable guide comprises a proximal end (21), a dista l end (22), and a guide body defining a lumen (13), and can optionally compris e a stable positioning element (16) for stably positioning a drug delivery device (50) within the guide. The guide can be provided in connection with a drug delivery device. In use, the guide is implanted within a subject so as to provide a conduit through which a drug delivery device can be retrievably introduced to facilitate delivery of drug to a treatment site within a subje ct at a site distal to an accessible implantation site. The drug delivery devic e is then positioned within the guide lumen to provide for delivery of drug fr om the drug delivery to the desired treatment site.

52. 发明专利

AU2164600A Controlled release system for delivering therapeutic agents into the inner ear 未知
公开(公告)号：AU2164600A
公开(公告)日：2000-06-26
申请号：AU2164600
申请日：1999-12-03
申请人： DURECT CORP
发明人： ARENBERG IRVING K , ARENBERG MICHAEL H , LEMKE CHRISTINE , BERGLUND JOHN A , THEEUWES FELIX
IPC分类号： A61F11/00 , A61K9/00 , A61K9/22 , A61M31/00
摘要： The present invention provides devices for controlled delivery of a therapeutic agent to an internal cavity of the ear, particularly to the inner ear. In general, the invention uses a drug delivery unit for inner ear treatment which employs a portion of carrier media material containing one or more therapeutic agents therein. The carrier media material is designed to release the therapeutic agents in a controlled manner over time. The drug delivery unit is shaped and sized for placement of at least a portion thereof in the round window niche of a patient. The released therapeutic agents come in contact with the round window membrane and pass therethrough into the inner ear for treatment purposes. This system provides many benefits ranging from the ability to deliver drugs in a site specific, highly controlled manner to the transfer of such materials with minimal patient discomfort and monitoring requirements.

53. 发明专利

DK2167039T3 FORBEDREDE DEPOTFORMULERINGER 未知
公开(公告)号：DK2167039T3
公开(公告)日：2017-01-09
申请号：DK08767765
申请日：2008-05-16
申请人： DURECT CORP
发明人： WRIGHT JEREMY C , THEEUWES FELIX , GIBSON JOHN W , BRANHAM KEITH E , SJOBECK STEFANIA
IPC分类号： A61K9/08

54. 发明专利

AU2011336896B2 Biodegradable drug delivery composition 未知
公开(公告)号：AU2011336896B2
公开(公告)日：2015-12-24
申请号：AU2011336896
申请日：2011-11-23
申请人： DURECT CORP
发明人： VAN OSDOL WILLIAM W , YUM SU IL , THEEUWES FELIX , SEKAR MICHAEL , GIBSON JOHN , BRANHAM KEITH , SU HUEY-CHING
IPC分类号： A61K38/08
摘要： The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

55. 发明专利

CA2932300A1 USES OF OXYGENATED CHOLESTEROL SULFATES (OCS) 未知
公开(公告)号：CA2932300A1
公开(公告)日：2015-07-02
申请号：CA2932300
申请日：2014-12-23
申请人： UNIV VIRGINIA COMMONWEALTH , DURECT CORP
发明人： REN SHUNLIN , THEEUWES FELIX , BROWN JAMES E , LIN WEIQI
IPC分类号： A61K31/575 , A61K31/56 , A61P43/00
摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

56. 发明专利

ZA201302120B BIODEGRADABLE DRUG DELIVERY COMPOSITION 未知
公开(公告)号：ZA201302120B
公开(公告)日：2014-05-28
申请号：ZA201302120
申请日：2013-03-20
申请人： DURECT CORP
发明人： VAN OSDOL WILLIAM W , YUM SU IL , THEEUWES FELIX , SEKAR MICHAEL , GIBSON JOHN A , BRANHAM KEITH , SU HUEY-CHING
IPC分类号： A61K20060101
摘要： The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

57. 发明专利

AU2008254538B2 Improved depot formulations 未知
公开(公告)号：AU2008254538B2
公开(公告)日：2013-11-07
申请号：AU2008254538
申请日：2008-05-16
申请人： DURECT CORP
发明人： BRANHAM KEITH E , WRIGHT JEREMY C , SJOBECK STEFANIA , GIBSON JOHN W , THEEUWES FELIX
IPC分类号： A61K9/08 , A61K9/10 , A61K31/519 , A61K47/06 , A61K47/34
摘要： Disclosed are formulations and related methods that comprise a non- polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37°C that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.

58. 发明专利

CA2583642C TRANSDERMAL DELIVERY SYSTEMS 未知
公开(公告)号：CA2583642C
公开(公告)日：2013-06-25
申请号：CA2583642
申请日：2005-10-21
申请人： DURECT CORP
发明人： YUM SU IL , THEEUWES FELIX
IPC分类号： A61K9/70 , A61K31/445
摘要： Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

59. 发明专利

CA2363705C DEVICES AND METHODS FOR PAIN MANAGEMENT 未知
公开(公告)号：CA2363705C
公开(公告)日：2013-06-11
申请号：CA2363705
申请日：2000-03-16
申请人： DURECT CORP
发明人： JOHNSON RANDOLPH MELLUS , THEEUWES FELIX
IPC分类号： A61K31/4468 , A61M37/00 , A61K9/00 , A61K9/08 , A61K9/22 , A61K9/70 , A61K31/4535 , A61K47/10 , A61K47/14 , A61K47/26 , A61M5/00 , A61P25/04
摘要： The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e., no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).

60. 发明专利

PL2216018T3 Transdermalne systemy dostarczania 未知
公开(公告)号：PL2216018T3
公开(公告)日：2012-09-28
申请号：PL10003544
申请日：2005-10-21
申请人： DURECT CORP
发明人： YUM SU IL , THEEUWES FELIX
IPC分类号： A61K9/70 , A61K31/445

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式